Biotechnology Company Announces Successful Preclinical Study Results For Psoriasis Treatment
Biotechnology Company Announces Successful Preclinical Study Results For Psoriasis Treatment
Promising In-Vivo Results for Scinai Immunotherapeutics' Psoriatic Human Skin Model.
Disclaimer: This article is intended for informational purposes only and does not constitute medical advice or endorsement of any product. Consult with a healthcare professional for medical advice and treatment options.
Real-time information is available daily at https://stockregion.net
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biotechnology company known for its focus on developing inflammation and immunology (I&I) biological products, has announced successful in-vivo preclinical study results. The results pertain to its innovative anti IL-17A/F VHH antibody fragment, known as 'NanoAb', which functions as a local intralesional biological treatment specifically designed for patients suffering from mild to moderate plaque psoriasis.
Understanding Plaque Psoriasis
Plaque psoriasis is a chronic autoimmune condition characterized by the rapid growth of skin cells leading to thick, red, scaly patches that can be itchy and painful. This condition affects approximately 13 million people across seven major markets including the US, EU5, and Japan. Among these individuals, around 50% endure mild psoriasis while 28% suffer from moderate forms of the disease. Patients diagnosed with mild to moderate plaque psoriasis often contend with significant visible lesions. These lesions can emerge on sensitive and highly visible areas such as the face, genitals, scalp, palms, and soles of the feet. Consequently, the condition not only causes physical discomfort and pain but also adversely affects patients' social interactions and mental well-being.
The current therapeutic approaches for managing mild to moderate plaque psoriasis primarily include topical corticosteroids and phototherapy. Topical corticosteroids, although effective, require frequent application and carry risks of local adverse effects such as skin atrophy and the development of tolerance. Moreover, these treatments often suffer from poor patient adherence due to the stringent treatment schedules. For moderate to severe cases, systemic therapies such as biologics and Janus kinase (JAK) inhibitors are commonly administered. While these treatments are highly effective, they are expensive, necessitate chronic use, and pose long-term health risks. As a result, there is a compelling need for improved treatment options that balance efficacy, safety, and patient adherence.
Scinai Immunotherapeutics aims to bridge the gap in the current treatment landscape with its NanoAb product candidate. This biologic is designed for localized intradermal delivery directly into psoriatic lesions using a short and minimally invasive needle. The goal is to offer patients with mild to moderate psoriasis a low-frequency treatment option that combines the high specificity and potency of biologics with a reduced risk of local and systemic side effects.
Key Advantages of NanoAb
Localized Delivery: Unlike systemic biologics, NanoAb is delivered directly into the affected skin lesions, minimizing systemic exposure and potential side effects.
Reduced Treatment Frequency: Patients benefit from a less frequent administration schedule compared to the daily or weekly use required for topical corticosteroids.
High Specificity and Potency: NanoAb targets specific cytokines involved in psoriasis pathology, providing potent anti-inflammatory effects with precision.
The preclinical study was led by Prof. Amos Gilhar, a leading researcher and dermatologist at the Technion, Israel Institute of Technology. The study aimed to evaluate the effectiveness of local intralesional treatment with NanoAb in comparison to traditional corticosteroids and systemic biologics. Human skin was transplanted onto SCID-Beige mice, a model that closely replicates human plaque psoriasis tissue morphology and cytokine profile. Psoriasis was induced in these mice through the injection of activated human peripheral blood mononuclear cells (PBMCs) from psoriasis patients. The mice were then divided into various study groups and treated for two weeks.
The primary objective was to assess whether the local administration of NanoAb could achieve an anti-inflammatory effect on psoriatic lesions that is at least non-inferior to that of corticosteroids and systemic biologics. The study yielded promising results, demonstrating that NanoAb effectively reduced inflammation in psoriatic lesions. The localized treatment approach not only matched the anti-inflammatory efficacy of corticosteroids and systemic biologics but also achieved this with fewer adverse effects. These findings suggest that NanoAb holds great potential as a novel therapeutic option for patients with mild to moderate plaque psoriasis.
The promising results from Scinai Immunotherapeutics' preclinical study mark a significant step forward in the treatment of mild to moderate plaque psoriasis. With its localized administration and potent anti-inflammatory effects, NanoAb has the potential to address many of the limitations associated with current treatment options. As Scinai continues to advance its research and development efforts, the hope is that this innovative therapy will eventually offer a safer, more effective, and patient-friendly solution for millions of individuals living with plaque psoriasis.
Disclaimer: This article is intended for informational purposes only and does not constitute medical advice or endorsement of any product. Consult with a healthcare professional for medical advice and treatment options.
Real-time information is available daily at https://stockregion.net